Special Issue "Advances in Pharmaceutical Applications of Lipid-Based Nanoparticles"
Deadline for manuscript submissions: 20 October 2023 | Viewed by 186
Interests: lipid/protein nanoassemblies; liquid crystalline phases; cubosomes; self-assembled nanostructures and nanoparticles with neuroprotective properties; nanomedicine; nanocarriers for macromolecular drug delivery; membrane receptor nanoscale organization; lipids; peptides; proteins; BDNF; cyclodextrin; soft nanomaterials
Special Issues, Collections and Topics in MDPI journals
Special Issue in Molecules: Advanced Self-Assembled Nanostructures
Special Issue in Nanomaterials: Progress in Pharmaceutical Applications of Lipid-Based Nanoparticles
Special Issue in Molecules: Women in Physical Chemistry
Special Issue in Nanomaterials: Self-Assembly, Synthetic and Biomimetic Nanostructures
Lipid-based nanomaterials and nanoparticles have gained considerable interest in vaccine development, targeted drug delivery, diagnostic imaging, and nanomedicine. They offer possibilities for the encapsulation of both hydrophilic and hydrophobic bioactive guest molecules in nanoscale reservoirs for controlled drug release. Lipid-based nanoparticles represent safe systems for the nanoformulation of mRNA, antimicrobial peptides, protein drugs, anti-viral, anti-inflammatory and anticancer agents, as well as for the delivery of nonviral gene-editing CRISPR-Cas9 complexes.
This Special Issue of Nanomaterials will focus on recent advances and ongoing cutting-edge research in the development of lipid nanoparticles (LNPs), liquid crystalline nanocarriers (cubosomes, spongosomes, hexosomes, and liposomes), nanostructured lipid carriers, solid lipid nanoparticles, and lipid–drug conjugates for potential new applications. The uses of LNPs and lipid-based nanomaterials as mono- and multidrug sustained delivery systems and their therapeutic uses in anti-viral therapies, cardioprotection, regenerative nanomedicine, slowing down of neurodegenerative disorders, and treatment of cancer, inflammation and infection diseases will be highlighted, among other possible applications. The preclinical and clinical status and the future prospects for lipid nanoparticle uses in diagnostics imaging, topical, intranasal, oral, and parenteral drug delivery as well as brain targeting will be considered. Remarkable attention will be given to the role of nanoparticle architectures and surface modifications in their cellular uptake mechanism.
Dr. Angelina Angelova
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lipid nanoparticles (LNPs)
- liquid crystalline nanocarriers
- nanostructured lipid carriers
- anti-viral therapeutics
- mRNA therapeutics
- siRNA therapeutics
- protein therapeutics
- peptide therapeutics
- CRISPR-Cas9 delivery
- controlled drug release
- drug–lipid conjugates
- lipids in therapy
- intranasal delivery